Status:
RECRUITING
REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Infertility
Eligibility:
FEMALE
Brief Summary
This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intrac...
Eligibility Criteria
Inclusion
- Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey.
Exclusion
- No exclusion criteria because data are collected under conditions of use in daily practice.
Key Trial Info
Start Date :
September 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 22 2029
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06545877
Start Date
September 16 2022
End Date
June 22 2029
Last Update
August 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ferring Investigational Site
Omitama, Ibaraki, Japan